Please login to the form below

Not currently logged in
Email:
Password:

Sanofi’s Guillaume Pfefer joins Kala as CEO

Leaves role as general manager of Sanofi Pasteur Mexico to join the US biopharma company

Former Sanofi executive Guillaume Pfefer has been appointed president and CEO of Kala Pharmaceuticals.

Pfefer will leave his position as general manager of Sanofi Pasteur Mexico to join the US biopharma. The company is developing medicines that can penetrate mucosal tissue to treat conditions affecting the eye, lung, gastrointestinal tract and female reproductive system.

“Guillaume is a proven industry leader with an impressive track record for managing high-performance teams and building significant company value” said Dr Robert Tepper, a member of the Kala board of directors.

“Under his leadership, and with the expertise of the existing Kala team, the company has the people, technology, and strategy to aggressively advance its therapeutic development programmes.”

He spent nine years at Sanofi, serving as VP, global head of Sanofi Pasteur's influenza and pneumococcal franchise and as global head of corporate strategy before landing his job in Mexico.

Prior to this time, Dr Pfefer held executive management positions with Aventis and Rhone-Poulenc.

He said: “Kala has developed an innovative approach to transform treatments for a range of serious diseases. A strong team is in place and together we will further advance a pipeline of innovative drugs that have potential to offer superior efficacy and address unmet clinical needs for debilitating respiratory, ophthalmic, female reproductive tract and gastrointestinal diseases.”

16th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics